Filing identity and reporting period
Important issuer mismatch: The supplied filing is Isoray, Inc.’s Form 10-Q, not a filing for Perspective Therapeutics, Inc. It covers the quarter and six months ended December 31, 2020, Isoray’s fiscal second quarter of fiscal 2021. The filing was signed February 9, 2021.
Isoray manufactures Cesium-131 brachytherapy seeds (Cesium Blu) for cancer treatment. Financial amounts below are in millions of dollars unless otherwise noted.
Financial performance and position
| Metric | Three months ended Dec. 31, 2020 | Six months ended Dec. 31, 2020 | Prior-year comparable |
|---|---|---|---|
| Net sales | $2.359 | $4.743 | $2.206 quarter; $4.521 six months |
| Gross profit / margin | $1.167 / 49% | $2.413 / 51% | $1.111 / 50% quarter; $2.347 / 52% six months |
| Operating loss | $(0.873) | $(1.587) | $(0.903) quarter; $(1.739) six months |
| Net loss | $(0.868) | $(1.581) | $(0.897) quarter; $(1.713) six months |
| Loss per share | $(0.01) | $(0.02) | $(0.01) quarter; $(0.03) six months |
- Six-month operating cash use was $1.098 million, versus $1.931 million a year earlier. Investing cash use was $0.173 million; financing provided $8.465 million, primarily from the October stock offering. Cash, cash equivalents and restricted cash rose by $7.194 million to $9.767 million.
- At December 31, cash and cash equivalents were $9.585 million; working capital was $10.954 million and the current ratio was 9.21. Total liabilities were $2.740 million, including $0.897 million of lease liabilities. The filing reports no off-balance-sheet arrangements.
- Sales rose 7% for the quarter and 5% for the six-month period. Other application sales increased 92% and 98%, respectively, while prostate brachytherapy sales fell 4% and 6%. Other applications grew to 20% of sales from 11% a year earlier.
Changes, outlook, and key risks
- Quarterly gross margin declined to 49% from 50%; six-month gross margin declined to 51% from 52%. Management cited higher isotope freight and material costs, unused isotope from lower-than-anticipated volume, and higher production labor costs.
- Management attributed weaker prostate procedure volumes in part to COVID-19-related delays and cancellations. It said the Blu Build loader and growth in brain and other applications supported sales; GammaTile-related sales were less than 10% of sales in each reported quarter.
- Management’s fiscal 2021 growth objective was approximately 25% revenue growth; the company missed that target in the first six months. Reaching cash-flow break-even in three to four years was conditional on achieving and sustaining the targeted growth and avoiding extraordinary expenses. The filing provides no firm revenue or earnings guidance.
- After quarter-end, the company reported approximately $7.9 million of proceeds from warrant and option exercises in January/early February. On February 8, it completed a common-stock offering for approximately $45 million gross proceeds, plus a fully exercised overallotment for approximately $6.75 million gross. It estimated net proceeds of approximately $41.675 million from the base offering; the filing does not clearly state net proceeds for the overallotment. Management said it did not anticipate needing another capital raise to fund the next fiscal year.
- Key risks include dependence on Russian Cesium-131 supply and international freight, COVID-19 effects on hospital access and procedures, uncertain reimbursement, and customer concentration: approximately 41% of six-month revenue came from three customers, with about 25% from one customer group. Isotope supply arrangements and the alternative reactor arrangement carry supply and performance uncertainties.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. No legal proceedings were disclosed.
Important facts for investors to verify
- Confirm the intended issuer: the source document identifies Isoray, Inc., not Perspective Therapeutics, Inc.
- Review the dilution and warrant terms from the October 2020 offering and the February 2021 offerings, and reconcile the filing’s reported share count with subsequent issuances and exercises.
- Assess whether procedure volumes and the company’s growth assumptions are achievable amid COVID-19 conditions, customer concentration, and reimbursement uncertainty.
- Confirm the reliability and terms of Cesium-131 supply, including Russian reactor availability and the Medikor consignment arrangement.
- Track cash burn against the newly raised capital and management’s conditional break-even outlook.